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Loss-of-function mutations of the MECP2 gene at Xq28 are associated with Rett syndrome in females and with
syndromic and nonsyndromic forms of mental retardation (MR) in males. By array comparative genomic hybrid-
ization (array-CGH), we identified a small duplication at Xq28 in a large family with a severe form of MR associated
with progressive spasticity. Screening by real-time quantitation of 17 additional patients with MR who have similar
phenotypes revealed three more duplications. The duplications in the four patients vary in size from 0.4 to 0.8 Mb
and harbor several genes, which, for each duplication, include the MR-related L1CAM and MECP2 genes. The
proximal breakpoints are located within a 250-kb region centromeric of L1CAM, whereas the distal breakpoints
are located in a 300-kb interval telomeric of MECP2. The precise size and location of each duplication is different
in the four patients. The duplications segregate with the disease in the families, and asymptomatic carrier females
show complete skewing of X inactivation. Comparison of the clinical features in these patients and in a previously
reported patient enables refinement of the genotype-phenotype correlation and strongly suggests that increased
dosage of MECP2 results in the MR phenotype. Our findings demonstrate that, in humans, not only impaired or
abolished gene function but also increased MeCP2 dosage causes a distinct phenotype. Moreover, duplication of
the MECP2 region occurs frequently in male patients with a severe form of MR, which justifies quantitative screening
of MECP2 in this group of patients.
Introduction
Mutations and gross rearrangements of the MECP2
gene (MIM 300005) are associated with Rett syndrome
(MIM 312750), a progressive neurodegenerative disor-
der that affects almost exclusively females, with an es-
timated prevalence of ∼1 in 10,000–15,000 women.
Classical Rett is characterized by progressive loss of in-
tellectual functioning, fine and gross motor skills, and
communicative abilities; progressive microcephaly; and
the appearance of stereotypic hand movements, after a
period of normal development (Hagberg et al. 1983).
Additional features, including seizures, ataxia, hyper-
ventilation, scoliosis, and growth retardation are often
seen. Mutations and large deletions in the MECP2 gene
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are responsible for up to 80% of the classical Rett cases
among girls; the large deletions have made quantitative
analysis part of the diagnostic workup in girls with Rett
syndrome (Schollen et al. 2003; Ravn et al. 2005). Dif-
ferent genotype-phenotype correlation studies were re-
cently published (Amir et al. 1999; Amir and Zoghbi
2000; Kammoun et al. 2004). Initially, Rett syndrome
was considered to be an X-dominant condition lethal in
hemizygous males (Zoghbi 1988). However, since the
first description of a male patient with an MECP2 mu-
tation, several additional patients have been identified
(Meloni et al. 2000; Orrico et al. 2000). The phenotypes
presented by these males cover a large spectrum of neu-
rodevelopmental disorders. The classical Rett syndrome
in male patients is seen in those with aneuploidy of the
X chromosome and in those who are mosaic for an
MECP2 mutation. Lethal neonatal encephalopathy was
reported in males born to asymptomatic or mildly af-
fected carrier mothers who inherited the mutation that
normally causes the Rett phenotype in females (Zeev et
al. 2002). Milder cases are associated with mutations
that do not result in classical Rett in female carriers
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Table 1
Primer Sequences Used for qPCR Analysis, with Their Approximate Positions







NXF5 gca cac aaa atg tcc acg aaa acc agg atg gag gtg aag tca 100,900,000
66N11 gag ggt gac ggg aat atc ct tgg tgg ctg agc gga aa 152,396,750
SLC6A8 gct ggt cag att tgt gct tca g cca gac ccc aaa ctg cat tc 152,472,000
ABCD1 gaa ggc agc ctt gga aaa ga ggg caa tag tga agg ctt ctg t 152,522,450
314B3 tgg tgg atg gaa gaa cat tca c cgg caa ggg ctt cct ctt a 152,618,350
L1CAM ttc gtt cat tgg cca gta cag t tgg ccc ctg agc tgt ca 152,649,000
MECP2a tgc tgg atg aat aac cac aac ac gaa ggt ctc cag cca tca gaa g 152,826,100
MECP2-5′ tcc cag ctg aga gtc cat ctg cac gtc ttc tca acc taa tgg aat t 152,924,150
Z49258 gga tgg gac gct gct aca ga gga cat ggt atc agg tgg act ca 153,058,500
EDMD cat gca cgc tac cag cag cag tc gaa tga tgt gcc aga gac cgc 153,131,000
GDI1 cct gca acg aca tca aag aca ttt gcg ctt cat gtt ctc aa g 153,191,850
G6PD acg gac gtc atc tga gtt ggt cac cta ctg cag atg ctg tgt ct 153,325,650
115M6 cca aat gcc gtg cct ctt t tgg acc acg ttg ggt att ca 153,537,800
(Meloni et al. 2000; Couvert et al. 2001). Although
MECP2 mutations were initially reported as a frequent
cause of mental retardation (MR) in males, large cohort
studies have shown that these mutations in males are far
more rare than initially thought and that careful eval-
uation of the pathogenicity of each identified missense
mutation is required (Bourdon et al. 2003).
Array comparative genomic hybridization (array-
CGH) has become the method of choice for the detec-
tion of microdeletions and microduplications at high
resolution, providing direct information on the geno-
mic position of the aberration. We developed an X-
chromosome array with a resolution of 80 kb to screen
patients with suspected X-linked mental retardation
(XLMR) for X-chromosomal aberrations (Van Esch et
al. 2005; Bauters et al., in press). In this way, we iden-
tified a small duplication at Xq28, comprising the
L1CAM (MIM 308840) and MECP2 genes, in a large
family with severe XLMR associated with spasticity.
Next, we performed quantitative PCR (qPCR) analysis
for the MECP2 gene in 17 male patients with a com-
parable phenotype, 2 of whom are from families with
indicative linkage to Xq28. In this way, we identified
three additional patients with a small duplication at
Xq28. Genotype-phenotype correlation studies point to
the duplication of MECP2 as the underlying cause of
severe MR, adding a new mechanism for MR-associated




The study protocol was approved by the appropriate
institutional review board of the University Hospital of
Leuven, Belgium, and informed consent was obtained
from the parents of the affected patients and their
healthy family members.
Preparation of DNA
Genomic DNA from patients as well as from healthy
controls was isolated from peripheral blood by standard
procedures. DNA was dissolved in TE buffer at a con-
centration of 0.33 mg/ml and was stored at 4C.
Full-Coverage X-Chromosome Array-CGH
Production of the X array, probe preparation, and
hybridization on the array were performed essentially as
described elsewhere (Van Esch et al. 2005; Bauters et
al., in press). These protocols were mainly based on
those developed at the Sanger Center (Fiegler et al.
2003). For each hybridization, 3 mg each of the Cy5-
and Cy3-labeled probes with a specific activity of 40
was mixed together with 100 mg Cot-1 DNA (Invitro-
gen) and was hybridized for 40 h at 37C in humid
chambers. Arrays were scanned with the Agilent G2565BA
MicroArrayScanner System (Agilent), and the acquired
images were analyzed using the ArrayVision software
(Imaging Research). Spot intensities were corrected for
local background, and only those spots with Cy5 and
Cy3 signal intensities at least 1.7-fold above the local
background were further analyzed. Data normalization
was performed against the mean of the spot ratios of all
clones. Clones with opposite aberrant ratios in the color-
flip experiments were sequence verified (Bauters et al.,
in press).
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Real-Time Quantitation of DNA Copy Number
We used the comparative ddCt method (Sequence De-
tection System bulletin 2 [Applied Biosystems]) with
SYBR-green for confirmation of our array-CGH data.
Primers were designed with PrimerExpress software (Ap-
plied Biosystems) and can be found in table 1. We first
validated whether the efficiency of amplification of the
chosen primer sets was equal to that of the normalizer.
A primer set for the NXF5 locus at Xq22 (Jun et al.
2001) was used for normalization. The validation ex-
periments were performed on fourfold dilutions of ge-
nomic DNA, starting with 100 ng in the first dilution.
For relative quantitation, the reaction mixtures consisted
of qPCR Mastermix Plus for SYBR Green I (Eurogentec),
with 500 nM of each primer and 10 ng DNA in a total
volume of 25 ml. After an initial denaturation step for
10 min at 95C, thermal cycling conditions were 15 s
at 95C and 1 min at 60C for 40 cycles. Finally, the
dissociation curves for each reaction were determined.
All samples were run in duplicate on an ABI PRISM
7000 instrument, and two independent runs were per-
formed for all samples.
X Inactivation
Lymphocyte genomic DNA from the female subjects
was subjected to the androgen-receptor gene methyla-
tion assay for assessment of the methylation status, as
described by Allen et al. (1992). A ROX-labeled geno-
typing marker 100-500 (Applied Biosystems) was added,
and the samples were separated on an ABI PRISM 3100
automated DNA sequencer (Applied Biosystems) and
were analyzed with GeneScan analysis software (Applied
Biosystems) for peak position and area intensity calcu-
lations. These data were further processed with the use
of Excel.
MECP2 mRNA Expression
Total RNA from 107 Epstein-Barr virus (EBV)–trans-
formed peripheral blood lymphocytes (PBLs) was ex-
tracted with 1 ml TRIzol (Invitrogen) in accordance with
the manufacturer’s instructions. A total of 1 mg was re-
verse transcribed with Superscript II (Invitrogen), and
genomic DNA was removed by DNaseI (Roche) treat-
ment for 30 min at room temperature. Real-time quan-
titation by the SYBR-green method was performed on
1/20th of the cDNA with the MECP2 primers (MECP2-
cDNA-for: 5′-GCTCCAACAGGATTCCATGGT-3′;
MECP2-cDNA-rev: 5′-GAGGTCCTGGTCTTCTGAC-
TTTTC-3′), as described above. The housekeeping gene
b-actin (bACT-for: 5′-CACCCTGAAGTACCCCATCG-
3′; bACT-rev: 5′-TGCCAGATTTTCTCCATGTCG-3′)
was used for normalization. A validation experiment
was performed on serial cDNA dilutions.
Results
Clinical Descriptions of the Patients
Family L36.—This family is of Finnish origin and con-
sists of six affected males in three generations (fig. 1).
Affected males are briefly described below, and findings
are summarized in table 2.
The index patient, IV.1, the only living affected male,
was born after an uneventful pregnancy to healthy par-
ents, with birth parameters in the normal range (weight
4,305 g [90th percentile]; height 53 cm [75th percentile];
occipital-frontal circumference (OFC) 36 cm [90th per-
centile]). His mother had had a miscarriage 2 years ear-
lier. When he was first examined at age 6 mo, a delay
in psychomotor development was noted, with the pres-
ence of an increased peripheral muscle tone and axial
hypotonia. At 10 mo, posterior asymmetry of the skull
was observed, as well as generalized inactivity and hy-
potonia. Since the patient was 2 years of age, absence
seizures had been suspected, but repeated electronen-
cephalogram (EEG) examinations did not reveal any sig-
nificant pathology. An MRI scan performed at the same
age showed no evident structural anomalies but some-
what delayed myelination. Reevaluation at age 14 years
showed that the patient had profound MR and did not
walk. He had absence of speech and increased and very
brisk deep-tendon reflexes in both the upper and the
lower limbs. He had prominent ears, flat nasal bridge,
and posterior asymmetry of the skull, with a protruding
tongue and a tendency to hyperventilate when he was
nervous (fig. 1). His vision and hearing were normal, as
well as his growth, but he had relative microcephaly (1
SD). A control MRI was normal. Extensive etiological
examinations, including metabolic screening, karyotype,
FMR1 and MECP2 mutation analysis, and skin and
muscle biopsies, were normal.
Individual III.3 was born after an uneventful preg-
nancy and delivery. Very early, a delay in psychomotor
development was noted. He achieved independent sit-
ting and some crawling and was able to walk a few
steps with support at age 8 years, but he never stood or
walked independently. He did not develop any speech
and showed a hypotonic facies, including an open mouth,
drooling, and a protruding tongue. His growth was con-
sidered normal, but, at age 9 years, his head circumfer-
ence was 51 cm (10th percentile). He also had occipital
asymmetry of the skull and long slender fingers with
some clubbing of the nails. Since he was 10 years of age,
he had received treatment for epileptic seizures, and EEG
showed intermittent spike-wave discharges. He had re-
current respiratory infections and died of pneumonia at
age 12 years.
His younger brother, individual III.4, showed a similar
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Figure 1 Pedigrees of the four families (L36, S49, T33, and T88) in which duplications at Xq28 have been identified. Blackened squares
indicate affected males, and an asterisk (*) indicates the index patient of each family. Clinical pictures of index patients IV.1 (family L36) at
age 1.5 years and III.2 (family S49) at age 12 years are shown. Data from X-inactivation studies are boxed and are shown below each female
from whom we could obtain a DNA sample.
clinical course. His development was severely delayed,
and he was not able to walk or speak. He had frequent
and severe respiratory infections, and, at 24 years, he
was given the diagnosis of lung tuberculosis. Clinical
features similar to the other family members were noted,
and his growth was considered relatively normal. He
progressively developed spasticity in the lower limbs. At
age 24 years, repeated generalized tonic-clonic seizures
were noted, with poor response to anti-epileptic treat-
ment. He died at age 35 years of unknown causes.
The third brother, individual III.5, displayed a similar
neurological and clinical phenotype, with profound MR
and absence of speech. At age 10 years, an inoperable
meningioma was diagnosed, and the boy died at age 13
years due to a cerebral herniation caused by the growing
tumor. Neuropathology of the brain revealed, in addi-
tion to the large meningioma, diffuse gliosis of the white
matter, diffuse neuronal loss of the cortex, and some
degree of disturbed lamination of the cortex.
The clinical data for individuals II.4 and II.8 are
sparse, but, for both, the psychomotor development was
said to be similar to that of individual III.5, with pro-
found MR and absence of speech. They both died in
early infancy, probably from pulmonary infections. The
cognitive levels of the carrier females and nonaffected
males in this family are all within the normal range.
Linkage analysis performed previously on DNA from
available living family members, by use of a standard
set of polymorphic microsatellite markers spread over
the entire X chromosome, assigned the disease locus to
the region Xq28-Xqter, with a maximal LOD score of
1.23 at marker DXS52 at , with flanking mark-vp 0.0
ers DXS1190 and Xqter. Subsequent mutation analysis
of MECP2, residing in this genomic interval, did not
reveal any mutation in this gene.
Patient S49.—Patient S49 was born to healthy, un-
related parents after a normal pregnancy, with birth pa-
rameters within the normal range. He has one younger
healthy sister and an older brother with trisomy 21 (fig.
1). In the first years of life, he presented with feeding
problems and recurrent upper-airway infections. He was
able to walk independently at age 18 mo, but his gait
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Table 2
Summary of Clinical Data for the Four Families




TOTAL (%)L36 S49 T33 T88a
No. of affected men 6 1 3 3 13
Severe MR 6/6 1/1 3/3 2/2 12/12 (100)
OFC !3rd percentile 1/4 0/1 1/2 0/3 2/10 (20)
Facial hypotoniab 4/4 1/1 3/3 3/3 11/11 (100)
Absent speech 6/6 1/1 2/3 1/2 10/12 (83)
Limited speech 0/6 0/1 1/3 1/2 2/12 (17)
Never walked 5/6 0/1 2/3 0/2 7/12 (58)
Limited walking with support 1/6 1/1 1/3 2/2 5/12 (42)
Spasticity ( )LL 1 UL 4/4 1/1 2/2 2/2 9/9 (100)
Seizures 3/4 0/1 0/2 1/2 4/9 (44)
Severe infections 3/6 NA 1/1 1/2 5/9 (56)
Death before age 25 years 4/6 … 1/3 1/2 6/11 (55)
NOTE.—Data are no. of individuals with characteristic/no. of in-
dividuals analyzed, unless indicated otherwise. NA p data not avail-
able; LL p lower limbs; UL p upper limbs
a Individual III.2 was only 13 mo of age at evaluation.
b Facial phenotype for the deceased affected men was scored on the
basis of clinical pictures.
was very unsteady and atactic. During childhood, he had
two epileptic fits, and he attended a special school. Ex-
haustive investigations, including evoked potentials and
repetitive brain imaging, were all normal. Examination
at age 12 years showed an alert boy with normal growth
parameters and head circumference but with severe MR
and absence of speech (fig. 1). His neurological exami-
nation was distinct, with axial hypotonia and spastic
diplegia. His behavior was chaotic but social. High-res-
olution karyotype and FMR1 analysis were normal.
Family T33.—This family is of French origin, and three
males from two generations were affected (fig. 1). The
index patient, individual III.1, was first seen at age 4
years by a clinical geneticist. He had been able to walk
for a few steps since age 3 years and had developed
limited speech. Clinical examination showed a boy with
severely delayed development with normal height and
weight and a relatively small head circumference (1
SD). He had bilateral deafness and spasticity in the low-
er limbs with extension deficit of both knees, together
with axial and facial hypotonia. He had a narrow fore-
head, flat facies, and relatively large, low-set ears. He
experienced recurrent respiratory infections. MRI at
age 1 year showed no abnormalities except for a cyst of
the septum pellucidum and mild cortical atrophy. His
mother had two brothers with profound MR, individ-
uals II.2 and II.3. The youngest brother (II.3) died in
early infancy at age 3 years. He was profoundly retarded,
with absence of speech and motor development. The
older half-brother, individual II.2, never learned to speak
or walk. Examination at age 24 years showed a man
with profound MR, relatively small stature (156 cm;
!3rd percentile), and a head circumference of 55 cm
(50th percentile). He progressively developed spasticity,
which was more pronounced in the lower limbs, with
brisk tendon reflexes and positive Babinski sign. The
cognitive levels of the carrier females and nonaffected
males in this family are all within the normal range.
Exclusion mapping, with a set of 10-cM–spaced X-chro-
mosome markers, that was previously performed on
DNA from five available family members excluded the
majority of the X chromosome except for the region
from Xq27.2 to Xqter.
Family T88.—This family is of French origin and com-
prises three affected males from two generations (fig. 1).
The index patient, individual III.2, was seen at age 13
mo because of developmental delay with pronounced
axial and facial hypotonia. His growth parameters were
all within the normal range. A CT scan of the brain
showed mild enlargement of the ventricles. His mother
had two brothers with severe MR. The oldest brother,
individual II.1, had profound MR, seizures, absence of
speech, and limited motor skills with spasticity, which
was more pronounced in the lower limbs. He died at
age 24 years due to meningo-encephalitis. The youngest
brother, individual II.4, learned to walk at age 2 years
and developed limited speech. He has very shy behavior
and limited spasticity in the lower limbs. The cognitive
levels of the carrier females and nonaffected males in
this family are all within the normal range. As with
family T33, previously performed exclusion mapping ex-
cluded the majority of the X chromosome except the
Xq27.2-Xqter region.
Identification and Delineation of a Duplication
at Xq28
By X-chromosome array-CGH, we identified a small
duplication at Xq28 in family L36. The duplication was
evident from aberrant ratios of two adjacent clones
(RP11-314B3 and RP11-119A22) at 152.5–152.9 Mb
at Xq28 (fig. 2A). The log2 normalized Cy5/Cy3 ratios
obtained for these clones were both 0.7 when the DNA
of the L36 index patient was labeled with Cy5 and were
both0.9 when the sample was labeled with Cy3 (array-
CGH data are available in online-only appendix A).
Analysis of this apparent 0.4-Mb region with the En-
sembl and University of California–Santa Cruz (UCSC)
genome browsers revealed a gene-dense region includ-
ing the MR-related L1CAM and MECP2 genes. Other
genes within this region are AVPR2, ARHGAP4, ARD1,
RENBP, HCFC1, and IRAK1. The X-array clones flank-
ing the duplication, RP11-66N11 (152.3 Mb) and RP5-
865E18 (153.3 Mb), showed normal ratios. To delineate
the duplication more precisely, real-time quantitation
(qPCR) was performed with primer pairs at multiple
Figure 2 Identification of a duplication at Xq28 in family L36. A, X-chromosome array-CGH analysis of DNA (labeled with Cy5) from
patient IV.1 mixed with DNA (labeled with Cy3) from a control male. Log2 normalized ratios are plotted against the position on the X
chromosome (in Mb). Except for two polymorphic clones, the ratios for clones in unaffected genomic regions are within the normal interval
(0.36 to 0.36), whereas clones RP11-314B4 and RP11-119A22 at 153 Mb show ratios 10.60 (circled), which is indicative of a duplication.
The “gap” at 60 Mb represents the centromeric region for which no clones were available. B, Schematic representation of the Xq28 region
(152.20–153.20 Mb), showing the location of the qPCR primer sets, genomic clones, and genes present in this interval for which qPCR primers
were designed. The duplicated region, based on the array-CGH and qPCR results, is shown below. C, qPCR data on DNA from the index
patient of family L36 (unblackened bars), as well as from two controls (Co1 and Co2 [blackened bars and gray bars, respectively]). The values
for the fold differences obtained for each primer set are given above the bars for the L36 patient only.
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Figure 3 qPCR data obtained by use of the MECP2a primer set for DNA from two controls (Co1 and Co2 [blackened bars]) as well as
17 patients with XLMR (unblackened bars) who showed a phenotype similar to that presented by the index patient of family L36, who was
used as a positive control (gray bar). The values for the fold differences in comparison with controls are given above the bars. A duplication
was found in three additional patients from families S49 (patient 11), T33 (patient 16), and T88 (patient 17).
positions within and around the identified duplication
(fig. 2B). qPCR with primer sets 314B3, L1CAM, and
MECP2a, mapping within the aberrant region, con-
firmed the duplication; the fold differences, relative to
control DNA samples, were 2.2, 2.0, and 1.9, respec-
tively (fig. 2C). In addition, the proximally located
SLC6A8 and distally located MECP2-5′ primer sets re-
vealed fold differences of 2.2 and 1.9, respectively. The
values obtained for primer sets at the other tested po-
sitions were within the normal interval ( ). On1.12 0.1
the basis of these results, we delineated the duplication
within a 580-kb region, with a minimal size of 420 kb
(table 1). At the distal breakpoint, the opsin gene repeat
cluster (OPN1) is located.
Detection of Three Additional Patients with Small
Xq28 Duplications
In the next step, we selected 17 patients with a phe-
notype similar to that of the index patient of family L36.
Of these, 15 were patients with sporadic cases and 2
were index patients from families for which exclusion
mapping suggested linkage to the Xq28-Xqter region.
For checking of additional duplications, we used the
qPCR primer set MECP2a located in intron 2 of the
MECP2 gene. Strikingly, we found a duplication at this
region in 1 of the 15 sporadic cases and in both of the
two patients with familial cases. The fold differences for
these three patients were 1.98, 2.47, and 2.54, which
are indicative of a copy number of two, whereas this
value was 1.02  0.10 for all other samples (fig. 3).
Subsequently, the exact position and size of each aber-
ration was checked by qPCR as described above. Figure
4 schematically presents the results of this analysis. The
duplication in patient S49, with a minimal and maximal
size of 270 kb and 440 kb, respectively, is smaller than
that in L36. In T88, the duplication size limits are 540
kb and 660 kb, whereas the largest duplication is found
in T33, in which a 0.8-Mb region is involved. The critical
region duplicated in all four patients overlaps with that
present in S49 and includes the genes from L1CAM to
MECP2. The known MR gene SLC6A8 is only involved
in family L36, whereas GDI1 is duplicated in family
T33. Taken together, the proximal breakpoints of the
different duplications are present within a 250-kb region
just centromeric of L1CAM. The distal breakpoints are
located in a 300-kb interval just telomeric of MECP2
(fig. 4).
Segregation of the Duplication with the Disease
For those family members for whom we could obtain
a DNA sample, we analyzed the segregation of the Xq28
duplication by qPCR with the MECP2a primer set. The
segregation of the duplication in L36 could only be
tested on preserved fibroblast DNA from deceased in-
dividual III.4 (fig. 1). He also carried the duplication,
since the obtained fold difference by qPCR was 2.16
(fig. 5A). For patient S49, the duplication was also pre-
sent in his healthy grandmother (I.2) and mother (II.1),
who demonstrated fold differences of 1.57 and 1.62,
respectively, which is indicative of three copies instead
of the normal two (allele ratio in a carrier female vs. a
control female is 3/2). His sister (III.3) is not a carrier,
since the obtained value was 1.1 (fig. 5A). In families
T33 and T88, the aberration was detected in all affected
males tested (II.2 and III.1 in T33; II.4 and III.2 in T88)
but not in the unaffected males tested (II.6 in T33; III.1
in T88). In the female subjects, all obligate carriers (I.2
and II.1 in S49; I.1 and II.4 in T33; I.1 and II.2 in T88)
showed fold differences close to the 1.5 value. Moreover,
we were able to identify additional carriers in both fam-
ilies (II.5 in T33; II.3 in T88). Female II.1 in family T33
does not harbor the duplication. X-inactivation studies
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Figure 4 Schematic representation of the positions and sizes of the duplications at Xq28 in the four families with severe MR associated
with spasticity. The locations of the qPCR primer sets, genomic clones, and genes present in this interval for which qPCR primers were designed
are given. In the lower part, unblackened boxes represent normal regions, and blackened boxes are confirmed duplicated regions. The breakpoints
of the duplications are located within the dotted lines. The duplication identified by Meins et al. (2005) is shown at the bottom, as is the
common minimal duplicated region in all patients.
showed that all carrier females demonstrated extreme
(185%) or even complete (100%) skewing of one of their
X chromosomes (fig. 1). The X-inactivation status in the
females with a normal Xq28 dosage, III.3 in S49 and
II.1 in T33, were 76/24 and 67/33, respectively. No DNA
from female members of the L36 family was available
for analysis. MECP2 mRNA expression was studied by
real-time quantitation in EBV-transformed PBL cell lines
from the index patients of families L36, T33, and T88.
A significantly higher expression was obtained in all cell
lines derived from patients carrying the duplication,
clearly illustrating a twofold higher expression in these
patients than in controls (fig. 5B)
Discussion
X-chromosome–specific array-CGH is a powerful tool
to identify submicroscopic aberrations in patients and
families with suspected XLMR (Veltman et al. 2004; Van
Esch et al. 2005; Bauters et al., in press). By this method,
we identified a duplication of ∼0.5 Mb at Xq28 in a
large family with syndromic MR that encompasses the
MR-related SLC6A8, L1CAM, and MECP2 genes. The
main features present in the affected males in this family
were severe-to-profound MR, with onset at birth; axial
and facial hypotonia; progressive spasticity, predomi-
nantly of the lower limbs; seizures; and recurrent infec-
tions, leading to early death in four of them. The affected
males also shared some mild dysmorphic features, in-
cluding large ears and flat nasal bridge. On the basis of
this clinical appearance, we selected a cohort of 17 male
patients with a similar phenotype—including patients
from two families who have XLMR with suggested link-
age to Xq28—for quantitative analysis of the MECP2
gene. We identified three additional small and overlap-
ping duplications at the Xq28 region, all segregating
with the disease in the respective families.
The Xq27-q28 chromosomal region is frequently af-
fected by rearrangements, and at least 16 different males
with disomy of the distal part of chromosome Xq have
been reported (reviewed by Sanlaville et al. [2005]). In
five of them, the disomy is the result of aberrant pairing
at the pseudoautosomal Xq-Yq regions (Lahn et al.
1994; Novelli et al. 2004; Teek et al. 2004). In eight
patients, the disomies were due to a similar intrachro-
mosomal rearrangement, in which a duplicated Xq26.3-
qter or Xq27-qter segment was translocated to the
Xp22.3 band (Vasquez et al. 1995; Goodman et al.
1998; Lammer et al. 2001; Kokalj-Vokac et al. 2004).
In the remaining three patients, the duplication is the
result of a de novo X-autosome translocation (Akiyama
et al. 2001; Lachlan et al. 2004; Sanlaville et al. 2005).
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Figure 5 Segregation of the duplication with the disease and increased MECP2 expression. A, Segregation was investigated by qPCR
performed using the MECP2a primer set on all family members from whom we could obtain a DNA sample. The values for the fold differences
in comparison with controls are given above the bars. A blackened bar indicates a male carrier (fold difference ∼2), and a gray bar indicates
a female carrier (fold difference ∼1.5). B, Expression of MECP2 mRNA, by use of qPCR primers, in PBLs from the index patients of families
L36, T33, and T88 (blackened bars), compared with controls (Co1–Co3 [unblackened bars]). The values for the fold differences in comparison
with controls are given above the bars.
Compared with our cases, the duplicated regions in
these reported patients are much larger, ∼5–12 Mb, and
include the pseudoautosomal Xq region. Although the
clinical descriptions of these patient are not all com-
plete, they share many clinical features with the patients
in this study, including hypotonia, severe MR, mild fa-
cial dysmorphism, and proneness to infections (Sanla-
ville et al. 2005). However, hypoplastic genitalia and
cryptorchidism were not observed in our patients. It is
of interest that, in our families, the phenotypes are
highly similar, even though the duplication sizes are not
identical (0.4–0.8 Mb). The common region duplicated
in the four families is !450 kb and harbors 10 genes or
predicted transcripts (L1CAM, AVPR2, ARHGAP4,
ARD1A, RENBP, HCFC1, Cxorf12, IRAK1, MECP2,
and OPN1MW), of which only MECP2 and L1CAM
are known to be associated with CNS development and
function. L1CAM codes for the L1 cell-adhesion mol-
ecule (CAM) and belongs to a large class of immuno-
globulin superfamily CAMs that mediate cell-to-cell ad-
hesion, with highest expression throughout the nervous
system (Kenwrick et al. 2000). Mutations in this gene
are involved in X-linked hydrocephalus due to stenosis
of aqueduct of Sylvius (HSAS [MIM 307000]); MR,
aphasia, shuffling gait, and adducted thumbs (MASA
[MIM 303350]); and corpus callosum hypoplasia, re-
tardation, adducted thumbs, spastic paraplegia, and hy-
drocephalus (CRASH [MIM 312900]) syndromes. Thus
far, no small duplications that involve only L1CAM
have been reported, and it is not known if this gene is
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associated with a disease phenotype. Overexpression of
the L1CAM protein has been reported in different ma-
lignant tumors, where it might be involved in the me-
tastasis process (Thies et al. 2002). In the patients of
this study who have undergone brain imaging, no brain
anomalies were observed that fit with mutated L1CAM
phenotypes.
Recently, Meins et al. (2005) reported a duplication
of ∼430 kb within Xq28 in a young boy with severe
MR and features of Rett syndrome. The proximal bor-
der of this duplication was located 5′ of L1CAM, leav-
ing this gene intact, whereas the distal border mapped
within the FLNA gene. Combining their results and
ours, we are able to delineate a critical duplicated re-
gion, harboring MECP2 as the only MR-related gene.
Therefore, our data suggest that increased gene dosage
of MECP2 is the most likely explanation for the severe
MR phenotype present in our patients. We cannot, how-
ever, exclude an additional role for L1CAM in the neu-
rological phenotype, because the patient of Meins et al.
(2005) was not described as having spasticity. On the
other hand, the spasticity observed in our families is
progressive in nature, and the patient of Meins et al.
might have been too young to exhibit this feature. The
MR gene SLC6A8 is duplicated in family L36, whereas,
in family T33, GDI1 is involved in the duplication.
Since both are known to play a role in nonspecific MR,
a contributive role in the phenotypes of these families
cannot be excluded (D’Adamo et al. 1998; Hahn et al.
2002).
Interestingly, several studies have already shown evi-
dence for a dosage-sensitive role for MeCP2 in neuronal
plasticity and function. Samaco et al. (2004) performed
a high-throughput quantitation of MeCP2 expression
on a tissue microarray containing frontal cortex samples
from a heterogeneous group of patients with neurode-
velopmental disorders and from age-matched controls.
By this method, they detected abnormal MeCP2 ex-
pression, both decreased and increased, in all samples
derived from the patients with a neurodevelopmental
disorder, suggesting dysregulation of MeCP2 in these
disorders. Elevated MECP2 mRNA levels, present in
our patients, were also detected in lymphoblastoid cells
of the patient reported by Meins et al. (2005). Recently,
a transgenic mouse model that overexpresses the human
MECP2 gene under the control of its own promoter
was reported (Collins et al. 2004). The mice clearly
developed a progressive neurological disorder, including
seizures and spasticity, and died prematurely. Interest-
ingly, besides the progressive spasticity, the epilepsy sub-
types observed in these mice are similar to the absence
and tonic-clonic seizures diagnosed in some of the af-
fected men. The neurological phenotype in these ani-
mals was modulated by the levels of MeCP2, in that
higher protein levels resulted in more-severe pheno-
types. A similar finding was noticed in Mecp2 knockout
mice that were rescued with the mouse Mecp2 cDNA
(Luikenhuis et al. 2004). Increased dosage of the pro-
tein to 4–6-fold above normal values resulted in pro-
found motor dysfunction, including side-to-side sway-
ing, tremor, and gait ataxia (Luikenhuis et al. 2004).
This dosage sensitivity reflects the necessity of a tight
regulation of the Mecp2 protein level and function in
the CNS. Interestingly, Collins et al. (2004) already hy-
pothesized that MECP2 overexpression could lead to
a postnatal neurological phenotype in humans. Addi-
tional support for the pathogenicity of the identified X-
chromosome aberration is given by the consistent and
marked skewing present in the asymptomatic female
carriers in these families as well as in the family reported
by Meins et al. (2005). Large duplications affecting the
Xq28 region have been observed in a number of females,
most of whom were phenotypically normal because of
the preferential activation of the normal chromosome
X, as suggested in the present study in regard to the
carrier females. One recent report describes a duplica-
tion of the MECP2 gene in a girl with the preserved-
speech Rett variant (Ariani et al. 2004). However, Ar-
iani et al. did not investigate whether the entire gene
was duplicated in this female patient.
Altogether, these data point to a tight regulation of
MeCP2 expression in pre- and postnatal brain function.
This finding puts serious constraints on the applicability
of gene therapy for patients with Rett syndrome. Besides
the routine quantitative analysis of the MECP2 gene in
female patients who have Rett without a mutation, a
diagnostic quantitative workup should also be envi-
sioned for male patients with severe MR and neurolog-
ical symptoms.
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